TABLE 1.

Outcome of antifungal treatment in experimental murine C. albicans infection with a challenge dose of 2 × 104 CFU/ga

TreatmentTreatment start daybMean ± SD (P value) for:c
Survival (days)Kidney (log CFU/g) at demise (n = 10)Brain (log CFU/g) at demise (n = 10)Kidney (log CFU/g) on day 4 (n = 2)Brain (log CFU/g) on day 4 (n = 2)
Placebo8.3 ± 1.86.5 ± 1.64.5 ± 1.45.1 ± 0.74.2 ± 0.2
AMB−121 ± 0.0 (<0.001)1.5 ± 0.3 (<0.001)1.3 ± 0.3 (<0.001)2.8 ± 0.0d (0.065)3.2 ± 0.3 (0.033)
AMB021 ± 0.0 (<0.001)1.5 ± 0.3 (<0.001)1.4 ± 0.6 (<0.001)3.6 ± 0.5 (0.068)3.4 ± 0.1d (0.064)
AMB121 ± 0.0 (<0.001)1.8 ± 0.9 (<0.001)1.3 ± 0.3 (<0.001)4.0 ± 0.2d (0.12)3.8 ± 0.0d (0.144)
AMB218.9 ± 5.7 (<0.01)1.5 ± 0.4 (<0.001)1.6 ± 0.8 (<0.001)4.5 ± 1.1 (0.29)4.1 ± 0.3d (0.42)
AMB315.8 ± 8.0 (>0.05)2.8 ± 2.0 (<0.001)2.0 ± 1.5 (<0.01)4.6 ± 0.4d (0.24)4.5 ± 0.7d (0.33)
CFN−121 ± 0.0 (<0.001)1.5 ± 0.3 (<0.001)1.3 ± 0.3 (<0.001)2.2 ± 0.1d (0.052)2.5 ± 0.4 (0.033)
CFN021 ± 0.0 (<0.001)1.5 ± 0.3 (<0.001)1.3 ± 0.3 (<0.001)2.9 ± 0.5 (0.037)2.9 ± 0.6 (0.087)
CFN120.2 ± 2.4 (<0.001)1.9 ± 1.0 (<0.001)2.0 ± 1.6 (<0.01)2.9 ± 0.3d (0.051)3.3 ± 0.1d (0.038)
CFN219.1 ± 5.7 (<0.01)2.5 ± 1.3 (<0.001)1.4 ± 0.6 (<0.001)4.9 ± 0.7 (0.41)3.8 ± 0.2d (0.13)
CFN316.5 ± 7.1 (<0.05)3.4 ± 1.7 (<0.01)2.3 ± 1.4 (<0.01)5.9 ± 0.7d (0.18)4.6 ± 0.5d (0.22)
FLC−119.8 ± 2.0 (<0.001)5.3 ± 1.9 (>0.05)1.5 ± 0.8 (<0.001)3.5 ± 0.1d (0.09)3.7 ± 0.0d (0.1)
FLC019.6 ± 1.2 (<0.001)5.2 ± 2.4 (>0.05)2.4 ± 1.4 (<0.01)3.7 ± 0.1 (0.1)3.7 ± 0.0d (0.12)
FLC117.0 ± 2.5 (<0.001)6.2 ± 1.6 (>0.05)1.7 ± 1.1 (<0.001)4.3 ± 0.0d (0.17)3.5 ± 0.2d (0.047)
FLC214.5 ± 6.1 (<0.05)6.2 ± 1.5 (>0.05)2.5 ± 1.4 (<0.01)5.6 ± 0.0 (0.1)4.1 ± 0.0 (0.12)
FLC318.3 ± 4.6 (<0.01)6.6 ± 1.6 (>0.05)3.5 ± 1.4 (>0.05)5.9 ± 0.6 (0.17)4.4 ± 0.6 (0.3)
  • a Groups of 12 mice were used. AMB, amphotericin B; CFN, caspofungin; FLC, fluconazole.

  • b Start day of treatment relative to day of infection. −1, treatment began the day before infection; 0, treatment began the day of infection; 1, 2, or 3, treatment began 1, 2, or 3 days after infection, respectively.

  • c P values for days of survival are by the log rank test. P values for results for Kidneys and brains are by Student's t test comparing burdens with the placebo-treated group.

  • d Significance difference (P < 0.05 in two-tailed Student's t test) with the equivalent burdens measured at the time of demise.